|
Real-time
Euronext Paris
08:43:25 2026-08-13 am EDT
|
5-day change | 1st Jan Change | ||
| 155.50 EUR | 0.00% |
|
-3.95% | +30.67% |
| Aug. 04 | Marengo Therapeutics, Inc. and Ipsen S.A. Nominate First Drug Candidate Under Strategic Tristar Collaboration | CI |
| Aug. 03 | Jefferies Downgrades Ipsen to Underperform, Boosts PT | MT |
Company Valuation: Ipsen
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,621 | 8,279 | 8,912 | 9,155 | 9,770 | 12,749 | - | - |
| Change | - | 25.05% | 7.65% | 2.72% | 6.72% | 30.5% | - | - |
| Enterprise Value (EV) 1 | 6,758 | 7,894 | 8,860 | 9,020 | 9,225 | 11,517 | 10,508 | 9,713 |
| Change | - | 16.81% | 12.22% | 1.81% | 2.28% | 24.84% | -8.76% | -7.57% |
| P/E | 10.4x | 12.9x | 14x | 26.7x | 22.4x | 12.9x | 13.7x | 13.7x |
| PBR | 2.42x | - | 2.36x | 2.22x | 2.3x | 2.49x | 2.12x | 1.83x |
| PEG | - | 20.02x | -13.67x | -0.6x | 0.8x | 0x | -2.58x | -257.91x |
| Capitalization / Revenue | 2.31x | 2.74x | 2.85x | 2.69x | 2.49x | 2.8x | 2.79x | 2.69x |
| EV / Revenue | 2.36x | 2.61x | 2.83x | 2.65x | 2.35x | 2.53x | 2.3x | 2.05x |
| EV / EBITDA | 5.8x | 5.86x | 10.1x | 7.52x | 6.67x | 6.1x | 6.1x | 5.68x |
| EV / EBIT | 6.68x | 7.08x | 8.85x | 8.13x | 7.13x | 7.22x | 7.1x | 6.53x |
| EV / FCF | 8.31x | 9.02x | 12.5x | 11.6x | 8.93x | 8.93x | 9.06x | 8.39x |
| FCF Yield | 12% | 11.1% | 8.02% | 8.59% | 11.2% | 11.2% | 11% | 11.9% |
| Dividend per Share 2 | 1.2 | 1.2 | 1.2 | 1.4 | 1.4 | 1.535 | 1.532 | 1.655 |
| Rate of return | 1.49% | 1.19% | 1.11% | 1.26% | 1.18% | 0.99% | 0.99% | 1.06% |
| EPS 2 | 7.76 | 7.81 | 7.73 | 4.15 | 5.32 | 12.03 | 11.39 | 11.38 |
| Distribution rate | 15.5% | 15.4% | 15.5% | 33.7% | 26.3% | 12.8% | 13.5% | 14.5% |
| Net sales 1 | 2,869 | 3,025 | 3,128 | 3,401 | 3,929 | 4,553 | 4,571 | 4,743 |
| EBITDA 1 | 1,166 | 1,348 | 881.4 | 1,200 | 1,383 | 1,888 | 1,723 | 1,709 |
| EBIT 1 | 1,011 | 1,115 | 1,001 | 1,109 | 1,294 | 1,596 | 1,481 | 1,487 |
| Net income 1 | 646.6 | 647.5 | 647.2 | 347.3 | 444.5 | 1,002 | 960.3 | 951.3 |
| Net Debt 1 | 137.8 | -384.7 | -52.9 | -134.9 | -544.5 | -1,233 | -2,241 | -3,036 |
| Reference price 2 | 80.50 | 100.50 | 107.90 | 110.70 | 119.00 | 155.50 | 155.50 | 155.50 |
| Nbr of stocks (in thousands) | 82,243 | 82,380 | 82,599 | 82,700 | 82,100 | 81,990 | - | - |
| Announcement Date | 2/11/22 | 2/9/23 | 2/8/24 | 2/13/25 | 2/12/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 12.93x | 2.53x | 6.1x | 0.99% | 14.72B | |
| 34.6x | 12.64x | 25.73x | 0.57% | 1,088B | |
| 29.02x | - | - | 2.06% | 629B | |
| 31.76x | 7.4x | 15.37x | 2.76% | 440B | |
| 20.37x | 4.83x | 11.97x | 2.73% | 359B | |
| 21.72x | 5.63x | 14.03x | 2.85% | 291B | |
| 20.24x | 4.18x | 11.87x | 2.1% | 245B | |
| 26.11x | 6.86x | 12.2x | 2.42% | 225B | |
| 13.56x | 4.86x | 10.12x | 3.76% | 204B | |
| -42.19x | 6.04x | 34.06x | 2.43% | 168B | |
| Average | 16.81x | 6.11x | 15.72x | 2.27% | 366.39B | |
| Weighted average by Cap. | 24.61x | 8.23x | 18.67x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- IPN Stock
- Valuation Ipsen
Select your edition
All financial news and data tailored to specific country editions
